GSK plc

GSK plc EBITDA Margin

The EBITDA Margin of GSK plc (GSK.L) as of Nov 12, 2026 is 24.15 %. In the previous year, EBITDA Margin was 18.22 % — a change of 32.52% (higher).

EBITDA Margin

24.15 %

YoY

32.52%

Last updated:

EBITDA Margin of GSK plc is 2025 24.15 % . EBITDA Margin of GSK plc was 2024 18.22 % . It decreases by 32.52% higher compared to the previous year.

The GSK plc EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
26.10 GBP
Jan 1, 2019
23.25 GBP
Jan 1, 2020
24.22 GBP
Jan 1, 2021
22.30 GBP
Jan 1, 2022
23.10 GBP
Jan 1, 2023
23.30 GBP
Jan 1, 2024
18.22 GBP
Jan 1, 2025
24.15 GBP
The GSK plc EBITDA Margin history
YEAREBITDA MarginYoY
24.15 %+32.52%
18.22 %-21.78%
23.30 %+0.86%
23.10 %+3.60%
22.30 %-7.94%
24.22 %+4.17%
23.25 %-10.91%
26.10 %-1.77%
26.57 %+7.83%
24.64 %+30.92%
18.82 %-12.91%
21.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EBITDA Margin of GSK plc is 24.15 % in 2025.

EBITDA Margin of GSK plc changed from 18.22 % to 24.15 %, representing a 32.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin GSK plc since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's GSK plc with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — GSK plc

All Key Metrics — GSK plc